Stocks making the biggest moves premarket: Delta, Tesla, Moderna and others

South Africa News News

Stocks making the biggest moves premarket: Delta, Tesla, Moderna and others
South Africa Latest News,South Africa Headlines
  • 📰 CNBC
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 72%

These are the stocks posting the largest moves before the bell.

– Paccar gained 1.6% in the premarket after the truck maker's stock was upgraded to overweight from equal-weight at Morgan Stanley, which also raised its price target to $136 per share from $91. The firm said Paccar is among the industrial stocks poised to benefit from a sector recovery.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

South Africa Latest News, South Africa Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Stocks making the biggest moves in the premarket: Oracle, Boeing, Moderna and moreStocks making the biggest moves in the premarket: Oracle, Boeing, Moderna and moreThe stocks making the biggest moves in premarket trading include Oracle, Boeing, Moderna, and more.
Read more »

Moderna and Merck team-up to fight melanomaModerna and Merck team-up to fight melanomaVaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer
Read more »

Merck, Moderna share positive progress of potential skin cancer vaccineMerck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. FOX13
Read more »

Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Read more »

Merck, Moderna detail potential skin cancer vaccine progressMerck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Read more »



Render Time: 2025-03-01 00:54:33